WO2023190653A1 - 医薬製剤の滅菌法と包装体 - Google Patents
医薬製剤の滅菌法と包装体 Download PDFInfo
- Publication number
- WO2023190653A1 WO2023190653A1 PCT/JP2023/012751 JP2023012751W WO2023190653A1 WO 2023190653 A1 WO2023190653 A1 WO 2023190653A1 JP 2023012751 W JP2023012751 W JP 2023012751W WO 2023190653 A1 WO2023190653 A1 WO 2023190653A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- salt
- pyrido
- dihydro
- aqueous pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1468—Containers characterised by specific material properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
- A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
- A61L2/022—Filtration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2103/00—Materials or objects being the target of disinfection or sterilisation
- A61L2103/05—Living organisms or biological materials
Definitions
- an aqueous pharmaceutical composition containing AFDX0250 or a salt thereof is packaged in a manner that blocks light rays with a wavelength of 210 to 380 nm (particularly 216 nm to 310 nm and 372 nm). It has been found that by storing the drug in the body, decomposition of AFDX0250 or its salt due to exposure to light can be suppressed and stability of the preparation can be ensured.
- the content of benzodiazepine-6-one or its salt is not particularly limited.
- the lower limit of the content is preferably 0.0001% (w/v), more preferably 0.0003% (w/v), even more preferably 0.0005% (w/v), and even more preferably 0.001% (w/v).
- /v) is even more preferred, 0.0013% (w/v) is particularly preferred, 0.0015% (w/v) is particularly more preferred, 0.0017% (w/v) is particularly more preferred, 0.
- the aqueous pharmaceutical composition may include (R)-11-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b] [1,4] It is not necessary to contain pharmaceutically acceptable active ingredients other than benzodiazepine-6-one or a salt thereof. That is, (R)-11-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine -6-one or a salt thereof may be included as the only active ingredient.
- anionic surfactants include phospholipids.
- phospholipids include lecithin.
- nonionic surfactants include polyoxyethylene fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, polyoxyethylene castor oil, polyoxyethylene polyoxypropylene glycol, sucrose fatty acid ester, Examples include vitamin E TPGS.
- a high molecular weight polymer that can be used as an additive for pharmaceuticals can be appropriately blended into the aqueous pharmaceutical composition.
- high molecular weight polymers include methylcellulose, ethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxypropylmethylcellulose (hypromellose), carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose acetate succinate, hydroxypropyl
- examples include methylcellulose phthalate, carboxymethylethylcellulose, cellulose acetate phthalate, polyvinylpyrrolidone, polyvinyl alcohol, carboxyvinyl polymer, and polyethylene glycol.
- the pharmaceutical preparation of the present invention is not particularly limited as long as it can be accommodated in the package described below, and can be used in the form of preparations for eye diseases, such as eye drops, eye gels, injections, etc. be able to. It is particularly preferred that the pharmaceutical formulation of the invention is used as eye drops. These dosage forms can be manufactured according to conventional methods in the art.
- the primary packaging body does not have to be a transparent container.
- the material of the secondary package that indirectly accommodates the aqueous pharmaceutical composition is preferably made of plastic, cellulose, pulp, paper, etc. from the viewpoint of processability.
- the secondary packaging body does not have to be transparent, but from the viewpoint of internal visibility, the secondary packaging body may also be transparent. When the secondary packaging is transparent, it is sufficient that it is transparent enough that the inside can be visually recognized.
- polyethylene (PE) resin container refers to a container in which at least the portion that comes into contact with the aqueous pharmaceutical composition is made of polyethylene resin. do.
- polyethylene include low density polyethylene (LDPE), medium density polyethylene (MDPE), and high density polyethylene (HDPE).
- LDPE low density polyethylene
- MDPE medium density polyethylene
- HDPE high density polyethylene
- PP container container in which at least the portion that comes into contact with the aqueous pharmaceutical composition is made of polypropylene resin.
- a method for stabilizing benzodiazepin-6-one or a salt thereof is (R)-11-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11 - Packing an aqueous pharmaceutical composition containing dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine-6-one or a salt thereof in a package that blocks light rays with a wavelength of 210 to 380 nm.
- Example 2 Thermal stability test (2) The thermal stability of AFDX0250 in a pharmaceutical formulation was evaluated by visually confirming precipitates in the test formulation after storage under certain conditions.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hematology (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020247034479A KR20240165977A (ko) | 2022-03-30 | 2023-03-29 | 의약 제제의 멸균법과 포장체 |
| JP2024512652A JPWO2023190653A1 (cg-RX-API-DMAC7.html) | 2022-03-30 | 2023-03-29 | |
| EP23780662.5A EP4501329A4 (en) | 2022-03-30 | 2023-03-29 | METHOD FOR STERILIZING AND PACKAGING A PHARMACEUTICAL PREPARATION |
| CN202380030713.XA CN118946362A (zh) | 2022-03-30 | 2023-03-29 | 医药制剂的灭菌法和包装体 |
| CA3254890A CA3254890A1 (en) | 2022-03-30 | 2023-03-29 | METHOD FOR STERILIZING AND PACKAGING A PHARMACEUTICAL PREPARATION |
| US18/851,269 US20250213588A1 (en) | 2022-03-30 | 2023-03-29 | Sterilization method of pharmaceutical preparation and packaging |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022056765 | 2022-03-30 | ||
| JP2022-056765 | 2022-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023190653A1 true WO2023190653A1 (ja) | 2023-10-05 |
Family
ID=88202031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2023/012751 Ceased WO2023190653A1 (ja) | 2022-03-30 | 2023-03-29 | 医薬製剤の滅菌法と包装体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250213588A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4501329A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2023190653A1 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240165977A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118946362A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3254890A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202404607A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023190653A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4506347A4 (en) * | 2022-03-30 | 2026-03-25 | Santen Pharmaceutical Co Ltd | PROCESS FOR THE PRODUCTION AND PURIFICATION OF HIGH-PURITY COMPOUNDS |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993018772A1 (en) | 1992-03-18 | 1993-09-30 | Allergan, Inc. | Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists |
| JP2002521429A (ja) * | 1998-07-30 | 2002-07-16 | アラーガン・セイルズ・インコーポレイテッド | 老視の処置におけるコリン作動性剤 |
| WO2018039159A1 (en) * | 2016-08-22 | 2018-03-01 | Chase Pharmaceuticals Corporation | Muscarinic m2-antagonist combination |
| WO2022023496A2 (en) * | 2020-07-29 | 2022-02-03 | Universidade De Santiago De Compostela | Functionalized isonitriles and products, preparation and uses thereof |
| WO2022030489A1 (en) | 2020-08-04 | 2022-02-10 | Santen Pharmaceutical Co., Ltd. | Agent for treating myopia, preventing myopia and/or suppressing myopia progression |
| WO2022080397A1 (ja) * | 2020-10-14 | 2022-04-21 | 参天製薬株式会社 | 安定な医薬組成物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0318772A (ja) | 1989-06-16 | 1991-01-28 | Mitsubishi Cable Ind Ltd | 絶縁体の絶緑性能評価方法 |
| JP7253813B2 (ja) | 2020-08-07 | 2023-04-07 | 株式会社ユニバーサルエンターテインメント | 遊技機 |
-
2023
- 2023-03-29 JP JP2024512652A patent/JPWO2023190653A1/ja active Pending
- 2023-03-29 CN CN202380030713.XA patent/CN118946362A/zh active Pending
- 2023-03-29 CA CA3254890A patent/CA3254890A1/en active Pending
- 2023-03-29 TW TW112111985A patent/TW202404607A/zh unknown
- 2023-03-29 KR KR1020247034479A patent/KR20240165977A/ko active Pending
- 2023-03-29 WO PCT/JP2023/012751 patent/WO2023190653A1/ja not_active Ceased
- 2023-03-29 US US18/851,269 patent/US20250213588A1/en active Pending
- 2023-03-29 EP EP23780662.5A patent/EP4501329A4/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993018772A1 (en) | 1992-03-18 | 1993-09-30 | Allergan, Inc. | Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists |
| JP2002521429A (ja) * | 1998-07-30 | 2002-07-16 | アラーガン・セイルズ・インコーポレイテッド | 老視の処置におけるコリン作動性剤 |
| WO2018039159A1 (en) * | 2016-08-22 | 2018-03-01 | Chase Pharmaceuticals Corporation | Muscarinic m2-antagonist combination |
| WO2022023496A2 (en) * | 2020-07-29 | 2022-02-03 | Universidade De Santiago De Compostela | Functionalized isonitriles and products, preparation and uses thereof |
| WO2022030489A1 (en) | 2020-08-04 | 2022-02-10 | Santen Pharmaceutical Co., Ltd. | Agent for treating myopia, preventing myopia and/or suppressing myopia progression |
| WO2022080397A1 (ja) * | 2020-10-14 | 2022-04-21 | 参天製薬株式会社 | 安定な医薬組成物 |
Non-Patent Citations (4)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4506347A4 (en) * | 2022-03-30 | 2026-03-25 | Santen Pharmaceutical Co Ltd | PROCESS FOR THE PRODUCTION AND PURIFICATION OF HIGH-PURITY COMPOUNDS |
Also Published As
| Publication number | Publication date |
|---|---|
| US20250213588A1 (en) | 2025-07-03 |
| CN118946362A (zh) | 2024-11-12 |
| JPWO2023190653A1 (cg-RX-API-DMAC7.html) | 2023-10-05 |
| KR20240165977A (ko) | 2024-11-25 |
| CA3254890A1 (en) | 2025-04-09 |
| EP4501329A1 (en) | 2025-02-05 |
| EP4501329A4 (en) | 2026-03-25 |
| TW202404607A (zh) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6889789B2 (ja) | 高眼圧症及び緑内障を治療するための方法及び組成物 | |
| AU2016326572B2 (en) | Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations | |
| JP2025129261A (ja) | クロルヘキシジンを含有する医薬組成物 | |
| HK1252705A1 (zh) | 他喷他多肠胃外给药的稳定制剂 | |
| JP2022101629A (ja) | 安定な医薬組成物 | |
| KR20240165977A (ko) | 의약 제제의 멸균법과 포장체 | |
| JP7037349B2 (ja) | 水溶性粘稠化剤を含有する医薬組成物 | |
| WO2018235935A1 (ja) | 水溶性粘稠化剤を含有する医薬組成物 | |
| EP2952190B1 (en) | Stable aqueous solution | |
| EP4512404A1 (en) | Composition for ophthalmic use containing sepetaprost | |
| JP2019006753A (ja) | 水溶性粘稠化剤を含有する医薬組成物 | |
| JP2022123792A (ja) | 水性医薬組成物 | |
| JP6817877B2 (ja) | ドルゾラミド、高分子およびホウ酸を含有する医薬組成物 | |
| JP7269425B2 (ja) | 水性液剤 | |
| JP7792540B2 (ja) | 水性液剤 | |
| JP2024090829A (ja) | 滅菌容器に収容されるエピナスチン含有水性医薬組成物 | |
| WO2025079591A1 (ja) | セペタプロストを含有する点眼液 | |
| JP7160799B2 (ja) | タペンタドールの非経口投与用安定製剤 | |
| JP2025520938A (ja) | 注射用フェニレフリン組成物 | |
| JP2026027212A (ja) | 水性組成物 | |
| HK40071854B (en) | Pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23780662 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 18851269 Country of ref document: US Ref document number: 202380030713.X Country of ref document: CN |
|
| ENP | Entry into the national phase |
Ref document number: 2024512652 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2024129556 Country of ref document: RU |
|
| ENP | Entry into the national phase |
Ref document number: 20247034479 Country of ref document: KR Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1020247034479 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2023780662 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2023780662 Country of ref document: EP Effective date: 20241030 |
|
| WWP | Wipo information: published in national office |
Ref document number: 18851269 Country of ref document: US |